Investing.com - Oramed reported on Wednesday third quarter earnings that missed analysts' forecasts and revenue that topped expectations.
Oramed announced earnings per share of $-0.23 on revenue of $700K. Analysts polled by Investing.com anticipated EPS of $-0.2133 on revenue of $691.33K.
Oramed shares are down 68% from the beginning of the year, still down 85.51% from its 52 week high of $31.54 set on November 3, 2021. They are under-performing the Nasdaq which is down 24.54% from the start of the year.
Oramed follows other major Healthcare sector earnings this month
Oramed's report follows an earnings beat by J&J on April 19, who reported EPS of $2.67 on revenue of $23.43B, compared to forecasts EPS of $2.59 on revenue of $23.62B.
Pfizer had beat expectations on May 3 with first quarter EPS of $1.62 on revenue of $25.66B, compared to forecast for EPS of $1.49 on revenue of $24.1B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar